Company intelligence / Profile preview

Bellecapital

Ownership: Private
Employees: ~60
Development stage: Other

Overview

Bellecapital is a Zurich-based asset management and investment advisory firm founded in 2009. It manages approximately 5 billion Swiss francs in assets, with a team of around 60 employees and offices in Zurich, London, the Cayman Islands, and Lausanne. The company offers actively managed equity funds to institutional and private clients across several high-conviction investment areas. While it is not itself a biotech or healthcare company, it does offer specialized thematic funds such as the Galileo Biotech Innovation Fund that invests in early-stage biotechnology companies focused on genome editing[1][2][8].

Industry: Investors

Partnerships

CAPinside (fintech partnership)

Beyond the preview

Go deeper on Bellecapital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bellecapital.

Explore the full profile